Skip to main
RGEN
RGEN logo

Repligen (RGEN) Stock Forecast & Price Target

Repligen (RGEN) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Repligen has raised its full-year 2025 revenue guidance to a range of $715-735 million, compared to the previous guidance of $695-720 million, indicating positive momentum in its financial performance. The company experienced a significant year-over-year growth in its CDMO segment and a robust 20% increase in biopharma revenue, showcasing strong demand across its customer base. Additionally, consumables sales surged by over 20%, complemented by a high-teens growth rate in capital equipment, further strengthening the outlook for continued revenue expansion.

Bears say

Repligen faces multiple inherent risks that contribute to a negative outlook on its stock, including the potential failure to successfully develop and launch new products, which could impede revenue growth. Additionally, the company's ability to close new mergers and acquisitions is crucial for expansion, and any shortcomings in this area may impact market position negatively. Furthermore, challenges related to market penetration and increasing competition, coupled with potential dilution risks, could adversely affect future profitability and shareholder value.

Repligen (RGEN) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Repligen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Repligen (RGEN) Forecast

Analysts have given Repligen (RGEN) a Buy based on their latest research and market trends.

According to 10 analysts, Repligen (RGEN) has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $169.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $169.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Repligen (RGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.